{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Y-mAbs Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"YMAB"},"Address":{"label":"Address","value":"230 PARK AVENUE,SUITE 3350, NEW YORK, New York, 10169, United States"},"Phone":{"label":"Phone","value":"+1 646 885-8505"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others."},"CompanyUrl":{"label":"Company Url","value":"https://www.ymabs.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Joris Wiel Jan Wilms","title":"Chief Operating Officer & Senior Vice President"},{"name":"Michael Rossi","title":"President, Chief Executive Officer & Director"},{"name":"Torben Lund-Hansen","title":"Chief Technology Officer & Senior Vice President"},{"name":"Vignesh Rajah","title":"Chief Medical Officer & Senior Vice President"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}